Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SUPPRESSION OF FOLLICULAR PHASE PITUITARY-GONADAL FUNCTION BY A POTENT NEW GONADOTROPIN-RELEASING-HORMONE ANTAGONIST WITH REDUCED HISTAMINE-RELEASING PROPERTIES (GANIRELIX)
Autore:
NELSON LR; FUJIMOTO VY; JAFFE RB; MONROE SE;
Indirizzi:
UNIV CALIF SAN FRANCISCO,CTR REPROD ENDOCRINOL,DEPT OBSTET GYNECOL & REPROD SCI SAN FRANCISCO CA 94143
Titolo Testata:
Fertility and sterility
fascicolo: 5, volume: 63, anno: 1995,
pagine: 963 - 969
SICI:
0015-0282(1995)63:5<963:SOFPPF>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
STIMULATING-HORMONE; POSTMENOPAUSAL WOMEN; LUTEINIZING-HORMONE; AGONISTIC ANALOG; ALPHA-SUBUNIT; NAFARELIN; TESTOSTERONE; ENDOMETRIOSIS; LEIOMYOMAS; SECRETION;
Keywords:
GANIRELIX; GNRH ANTAGONIST; PITUITARY-OVARIAN FUNCTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
L.R. Nelson et al., "SUPPRESSION OF FOLLICULAR PHASE PITUITARY-GONADAL FUNCTION BY A POTENT NEW GONADOTROPIN-RELEASING-HORMONE ANTAGONIST WITH REDUCED HISTAMINE-RELEASING PROPERTIES (GANIRELIX)", Fertility and sterility, 63(5), 1995, pp. 963-969

Abstract

Objective: To determine if daily subcutaneous doses of ganirelix willsuppress and maintain E(2) less than or equal to 30 pg/mL (conversionfactor to SI unit, 3.671), the serum profiles of LH and FSH during and after cessation of treatment, the time-course of the resumption of normal ovarian function after ganirelix cessation, and to identify sideeffects of daily treatment. Design: Open-label nonrandomized clinicalstudy. Setting: Normal human volunteers in an academic research center. Patients: Women 21 to 45 years of age, with documented ovulatory menstrual cycles. Interventions: Ganirelix was administered subcutaneously daily for 8 days. Blood samples were obtained during dosing as wellas before and after cessation of dosing. Main Outcome Measures: Changes in serum E(2), LH, FSH, P, and ganirelix. Results: Ganirelix treatment rapidly decreased serum levels of gonadotropins and E(2) after both 1 and 2 mg administration. Twenty-four hours after the first dose ofganirelix, E(2) decreased from a mean +/- SEM of 50 +/- 8 and 67 +/- 11 pg/mL at baseline to 25 +/- 4 and 20 +/- 3 in the 1 mg and 2 mg groups, respectively. Estradiol remained suppressed (mean levels < 26 pg/mL) on all subsequent 7 days of ganirelix dosing in both groups. Afterthe final dose of ganirelix, there was a rapid return of ovarian function in all volunteers. All women had P levels indicative of ovulationin the subsequent cycle, and the mean number of days from the final ganirelix dose to the next menses was 25.8 +/- 2.1 and 27.3 +/- 1.6 in the 1 and 2 mg groups, respectively. Conclusions: Daily ganirelix administration is effective in suppressing the pituitary-gonadal axis and has a side effect profile that should be well tolerated.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 03:11:07